Skip to content

GlobalRPh Renal Dosing Masterv6.8

Clinical interpretation | Version 6.8

Find the difference.
Keep the context.

Search documented disagreements and product cautions across the local library. Compare complete source versions on the drug page before choosing a regimen.

Search source differences

451 notes across 412 drug/product records.

How to interpret these notes

Generic name, brand, source or issueType of differenceAdded in v6.8

Clear filters Export all filtered notes

Search medication names and documented issues only. Do not enter patient information. This directory submits search filters to the server; the within-drug text finder remains a separate local feature.

A difference is not always a contradiction

Compare indication, formulation, route, population, renal method, dialysis conditions and source date. A safety update or source-quality failure is not an alternative dose. These notes are not independent clinical approval, and sources are not ranked or averaged.

451 matching notes. Showing 273-288; page 18 of 29.

dose table scope

Naloxegol tablets (Movantik, adults)

MOVANTIK: renal starting dose and conditional escalation

The higher dose is a conditional option after tolerance and inadequate response, not the default renal maintenance dose. CYP3A interactions can impose additional restrictions.

What to reconcile

Check the renal starting dose and interaction pathway before considering escalation.

1 source identities and dates

GlobalRPh RX List - MOVANTIK

GlobalRPh-hosted RX List | Source revision: RX page prints August 2017.
Naloxegol - MOVANTIK tablets; selected source sections, not a full prescribing monograph.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v4.8.

Open / share source review Open drug and compare sources Naldemedine - SYMPROIC tablets - related, not interchangeable

formulation scope

Naltrexone / bupropion - CONTRAVE ER tablets

CONTRAVE: a maximum does not replace titration

The qualitative renal ceiling belongs to a fixed combination. Parent-drug PK does not negate increased metabolite exposure.

What to reconcile

Do not invent numeric renal bands or apply this ceiling to naltrexone alone.

1 source identities and dates

GlobalRPh RX List - CONTRAVE

GlobalRPh-hosted RX List | Source revision: RX page prints May 2024.
Naltrexone / bupropion - CONTRAVE ER tablets; selected source sections, not a full prescribing monograph.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v4.8.

Open / share source review Open drug and compare sources Naltrexone - VIVITROL extended-release injection - related, not interchangeable

boundary units

Naratriptan tablets

Naratriptan: renal daily maximum and exact-15 wording

The renal daily maximum differs from the general maximum. The dosing and PK sections use different endpoint wording around CrCl 15.

What to reconcile

Do not use the general daily maximum or silently assign the ambiguous endpoint.

1 source identities and dates

GlobalRPh RX List - Naratriptan

GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Naratriptan tablets; selected source sections, not a full prescribing monograph.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v4.8.

Open / share source review Open drug and compare sources

source scope and renal guidance

Nateglinide - STARLIX oral tablets

Before use: Nateglinide - STARLIX oral tablets

No-adjustment wording coexists with ESRD metabolite accumulation; it is not a safety clearance.

What to reconcile

Confirm the exact product, indication, renal measure and full source before prescribing.

1 source identities and dates

GlobalRPh RX List - STARLIX oral tablets

GlobalRPh-hosted RX List | Source revision: STARLIX portion 10/2021; generic portion 4/2015
Adults with type 2 diabetes; selected STARLIX renal sections.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v6.3.

Open / share source review Open drug and compare sources

population scope

Nedosiran - RIVFLOZA injection

RIVFLOZA: renal eligibility is not age/weight dosing

The no-adjustment range does not extend into the unstudied PH1 severe-impairment range.

What to reconcile

Keep the PH1 indication and age/weight dose instructions separate from renal eligibility.

1 source identities and dates

GlobalRPh RX List - RIVFLOZA

GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Nedosiran - RIVFLOZA injection; selected source sections, not a full prescribing monograph.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v4.8.

Open / share source review Open drug and compare sources

guideline difference

Nelarabine - ARRANON injection

Nelarabine: label evidence gap versus qualitative eviQ guidance

The label cannot recommend a dose below CrCl 50. eviQ describes PK-based no adjustment in mild/moderate impairment but gives no numerical renal bands; scope alignment remains unresolved.

What to reconcile

Obtain oncology/pharmacy adjudication without assigning eviQ an invented cutoff; retain the neurotoxicity stopping rule.

2 source identities and dates

GlobalRPh RX List - ARRANON

GlobalRPh-hosted RX List | Source revision: RX page prints March 2025.
Nelarabine - ARRANON injection; selected source sections, not a full prescribing monograph.

Read this stored source

Nelarabine - eviQ protocol 4510 renal guidance

eviQ / Cancer Institute NSW | Source revision: eviQ protocol 4510, version 1; reviewed July 22, 2026; initial publication May 7, 2025.
Nelarabine - eviQ protocol 4510 renal guidance; selected source sections, not a full prescribing monograph.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v4.8.

Open / share source review Open drug and compare sources

source scope

Nerandomilast - JASCAYD tablets

JASCAYD: official guidance does not repair the RX rendering

The RX card is PK-only. The August 2026 official label separately supplies renal prescribing guidance and an ESRD restriction.

What to reconcile

Use the official section for prescribing scope while keeping the incomplete RX source flagged; neither is an independent validation of the same label.

2 source identities and dates

GlobalRPh RX List - JASCAYD

GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Nerandomilast - JASCAYD tablets; selected source sections, not a full prescribing monograph.

Read this stored source

Nerandomilast - JASCAYD official label

DailyMed / Boehringer Ingelheim Pharmaceuticals, Inc. | Source revision: Prescribing information revised 08/2026.
Nerandomilast - JASCAYD official label; selected source sections, not a full prescribing monograph.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v4.8.

Open / share source review Open drug and compare sources

formulation evidence gap

Nevirapine extended-release (VIRAMUNE XR)

XR source calls for an immediate-release dialysis supplement

The XR page discusses an immediate-release post-dialysis supplement while explicitly stating that XR has not been studied in renal dysfunction. That is not direct validation of an extra XR tablet.

What to reconcile

Verify the established antiretroviral regimen, precise release form and specialist plan. Retain the below-threshold evidence gap and hepatic/rash precautions; do not substitute a release form based on the common ingredient.

1 source identities and dates

GlobalRPh RX List - Viramune XR

GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
VIRAMUNE XR source discusses an immediate-release supplement; XR renal data are absent.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v4.0.

Open / share source review Open drug and compare sources Nevirapine - related, not interchangeable

formulation scope

Nilotinib - DANZITEN tablets

DANZITEN: lower product strengths are not renal reductions

The product-specific conversion strengths and food instructions differ from TASIGNA. Renal PK remains unknown.

What to reconcile

Use the named conversion pathway, not a milligram-for-milligram substitution or an inferred renal dose.

1 source identities and dates

GlobalRPh RX List - DANZITEN

GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Nilotinib - DANZITEN tablets; selected source sections, not a full prescribing monograph.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v4.8.

Open / share source review Open drug and compare sources Nilotinib - TASIGNA capsules - related, not interchangeable

evidence limit

Nilotinib - TASIGNA capsules

TASIGNA: unknown renal PK does not imply no adjustment

The renal PK effect is unknown. Electrolyte and QT safeguards remain clinically important.

What to reconcile

Do not create a renal table from source silence or transfer another nilotinib formulation schedule.

1 source identities and dates

GlobalRPh RX List - TASIGNA

GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Nilotinib - TASIGNA capsules; selected source sections, not a full prescribing monograph.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v4.8.

Open / share source review Open drug and compare sources Nilotinib - DANZITEN tablets - related, not interchangeable

source format discrepancy

Niraparib tablets (Zejula)

Mixed capsule and tablet descriptions on the RX source page

The retrieved RX page combines a capsule description with tablet dosage-form content. The selected renal statement is locally retained, but the mixed page is not used to resolve tablet strength or formulation.

What to reconcile

Use the exact tablet-label source for product selection, and check current oncology labeling. No capsule-to-tablet equivalence or updated indication is inferred from this extract.

2 source identities and dates

Niraparib tablets (Zejula) - selected U.S. label sections

U.S. product labeling / DailyMed | Source revision: Revision not captured; retrieval date is not the revision date.
ZEJULA film-coated tablets. This entry does not import an older capsule dosing regimen.

Read this stored source

GlobalRPh RX List - Zejula

GlobalRPh-hosted RX List | Source revision: January 2024 on retrieved RX page
Adult product-specific renal information; not a complete prescribing regimen.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v3.4.

Open / share source review Open drug and compare sources

dialysis scope

Nirmatrelvir/ritonavir (Paxlovid, adults)

PAXLOVID: day 1 differs from days 2-5 in severe impairment

The rechecked RX and official tables retain a day-specific severe-impairment course, with post-HD timing on dialysis days. The same regimen already existed locally.

What to reconcile

Check the treatment day, component doses, renal units and all interactions; a matching mirror is not independent corroboration.

2 source identities and dates

GlobalRPh RX List - PAXLOVID

GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Nirmatrelvir / ritonavir - PAXLOVID adult renal regimen; selected source sections, not a full prescribing monograph.

Read this stored source

Nirmatrelvir / ritonavir - PAXLOVID official renal regimen

DailyMed / Pfizer Laboratories Div Pfizer Inc | Source revision: Prescribing information revised 02/2026.
Nirmatrelvir / ritonavir - PAXLOVID official renal regimen; selected source sections, not a full prescribing monograph.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v4.8.

Open / share source review Open drug and compare sources

boundary units

Nirogacestat - OGSIVEO tablets

OGSIVEO: preserve the actual studied renal boundary

The selected PK population starts at indexed eGFR 41, not a conventional 30 threshold. Electrolyte monitoring is a separate requirement.

What to reconcile

Do not round the evidence boundary down or infer a replacement-electrolyte protocol.

1 source identities and dates

GlobalRPh RX List - OGSIVEO

GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Nirogacestat - OGSIVEO tablets; selected source sections, not a full prescribing monograph.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v4.8.

Open / share source review Open drug and compare sources

professional criterion vs label

Nitrofurantoin

MACROBID label and older-adult criteria use different renal thresholds

The label retains a CrCl-below-60 contraindication; the AGS 2023 older-adult criterion uses below 30. This difference does not establish safety for every patient between those values.

What to reconcile

Confirm population, lower-tract indication, duration and local policy. Document any departure from labeling; neither a source count nor this comparison selects a prescription.

2 source identities and dates

MACROBID renal contraindication - selected label

DailyMed / NLM; manufacturer prescribing information | Source revision: Source revision date not established in selected retrieval.
MACROBID nitrofurantoin monohydrate/macrocrystals, oral. Selected restriction, not a complete antibiotic regimen.

Read this stored source

AGS Beers 2023 - nitrofurantoin renal criterion

American Geriatrics Society expert panel | Source revision: 2023 AGS Beers Criteria, published May 4, 2023
Adults aged 65 years and older; AGS 2023 geriatric criteria, not universal adult guidance.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v3.4.

Open / share source review Open drug and compare sources

jurisdiction metric

Nitrofurantoin

Nitrofurantoin: U.K. indexed-eGFR advice is not the U.S. CrCl label

The added historical MHRA advice differs in renal measure, cutoff and limited lower-UTI exception from the retained U.S. label and geriatric/institutional sources. It is not a new 2026 U.S. rule.

What to reconcile

Keep jurisdiction, infection site, source date and renal estimator attached to each recommendation. Do not substitute one numerical cutoff for another without clinical adjudication.

2 source identities and dates

Nitrofurantoin - MHRA renal restriction perspective

U.K. Medicines and Healthcare products Regulatory Agency (MHRA) | Source revision: Article: September 2014; GOV.UK publication 2015-02-12. Selected advice rechecked 2026-09-08; not presented as a new 2026 guideline.
U.K. MHRA safety advice for nitrofurantoin; jurisdiction-specific comparison, not a replacement U.S. label.

Read this stored source

MACROBID renal contraindication - selected label

DailyMed / NLM; manufacturer prescribing information | Source revision: Source revision date not established in selected retrieval.
MACROBID nitrofurantoin monohydrate/macrocrystals, oral. Selected restriction, not a complete antibiotic regimen.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v4.4.

Open / share source review Open drug and compare sources

guideline difference

Nitrofurantoin

Nitrofurantoin: label, UCSF and UK guidance remain distinct

The label restriction, UCSF limited-data position and UK short-course exception differ in renal measure, setting and qualifications. UCSF is not an endorsement down to CrCl 30.

What to reconcile

Document jurisdiction and infection scope; preserve the UK multidrug-resistant lower-UTI and benefit-risk qualifications. Do not convert eGFR thresholds into CrCl cutoffs.

3 source identities and dates

GlobalRPh RX List - MACROBID

GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Nitrofurantoin - MACROBID label restrictions; selected source sections, not a full prescribing monograph.

Read this stored source

Nitrofurantoin - UCSF cystitis guidance

University of California San Francisco, Infectious Diseases Management Program | Source revision: Source revision date not established in selected retrieval.
Nitrofurantoin - UCSF cystitis guidance; selected source sections, not a full prescribing monograph.

Read this stored source

Nitrofurantoin - MHRA renal restriction perspective

U.K. Medicines and Healthcare products Regulatory Agency (MHRA) | Source revision: Article: September 2014; GOV.UK publication 2015-02-12. Selected advice rechecked 2026-09-08; not presented as a new 2026 guideline.
U.K. MHRA safety advice for nitrofurantoin; jurisdiction-specific comparison, not a replacement U.S. label.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v4.8.

Open / share source review Open drug and compare sources

What is not established by this directory

Only documented issues are searchable here. Absence of a note is not agreement. A label mirror and the original label are not independent corroboration, and a source's retrieval date is not its revision date.

See source and A-Z review status Home / all drugs